Skip to content

Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix.

Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix. Immunohistochemical Study on Biopsies (Retrospective and Prospective Analysis) and on Liquid Based (SurePath) Cervical Cytology (Prospective Analysis). Correlation With HPV Typing and Clinical Outcome.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00343213
Enrollment
300
Registered
2006-06-22
Start date
2006-06-30
Completion date
Unknown
Last updated
2011-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Intraepithelial Neoplasia Grade 1 (CIN 1)

Keywords

Prognostic value of p16INK4a, CIN 1, LSIL, HPV

Brief summary

P16INK4a has recently been described as a surrogate marker for HR-HPV associated squamous and glandular intraepithelial lesions of the cervix. The immunohistochemical staining pattern of p16INK4a in high grade intraepithelial neoplasia of the cervix (CIN 2 and 3) is diffuse, whereas in CIN 1 different staining patterns (diffuse, sporadic, focal or negative) can be seen. The aim of our study is to find out whether the p16INK4a staining pattern of CIN 1 is able to predict the outcome of the lesion. The retrospective part of the study includes cervical biopsies of 200 patients with CIN 1 and clinical follow-up for at least 5 years. p16INK4a staining and HPV detection by IHC will be correlated to clinical outcome.The prospective part of the study includes 300 patients with CIN 1 and LSIL on cytology. HPV detection by HCII and p16INK4a immunohistochemistry on liquid based cytology samples as well as p16INK4a staining and HPV detection by ISH on colposcopy guided biopsies will be correlated to clinical follow-up and colposcopy findings. Slides are analysed by 2 pathologists without knowledge of clinical data.

Interventions

PROCEDUREcolposcopy

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Responsible women \> 18 years with histologically proven CIN 1

Design outcomes

Primary

MeasureTime frame
p16INK4a staining pattern and HPV status of the initial biopsy

Secondary

MeasureTime frame
p16INK4a staining pattern and histologic diagnosis of follow-up biopsies correlated with colposcopic findings.

Countries

France

Contacts

Primary ContactJean-Jacques Baldauf, MD
jean-jacques.baldauf@chru-strasbourg.fr3.33.88.12.74.59
Backup ContactGerlinde Averous
gerlinde.averous@chru-strasbourg.fr3.33.88.12.70.52

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026